Intrinsiqq
Eterna Therapeutics Inc. logo

Eterna Therapeutics Inc. Financials

ERNA

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 17 available years
Income Statement
TTM
DEC 2025
7:1 split
DEC 2024
DEC 2023
~1.7:1 split
DEC 2022
~1.4:1 split
DEC 2021
~2.5:1 split
Revenues
Revenue$1–$1$0$0–
Cost of Revenue$0–$0$0$0–
Gross Profit$0–$0-$0$0–
General & Administrative$13$5$13$15$17$15
Research & Development$5$4$5$6$10$13
Total Operating Expenses$16$9$16$21$33$114
Operating Income-$16-$9-$16-$21-$33-$114
Non-Operating
Net Interest Expense-$1-$0-$1-$0-$0–
Other Non-Operating Income (Expense)-$27-$5-$28-$0$9-$9
EBT (Earnings Before Tax)-$45-$14-$45-$22-$25-$122
Income Tax Expense$0-$0$0-$0$0$0
Net Income
Net Income-$45-$14-$45-$22-$25-$123
Per Share Data
Revenue Per Share$15.99–$15.99$4.80$0.00–
EPS (Basic)-$1,224.00-$56.00-$1,224.00-$1,530.00-$3,022.50-$21,225.00
EPS (Diluted)-$1,224.00-$56.00-$1,224.00-$1,530.00-$3,022.50-$21,225.00
Weighted Avg Shares (Basic)13.6M6.3M13.6M5.3M3.1M43.3M
Weighted Avg Shares (Diluted)13.6M6.3M13.6M5.3M3.1M43.3M
Shares Outstanding36,392252,28036,39214,170.6678,1365,774.133

Eterna Therapeutics (ERNA) financials: revenue, profit and margins

Eterna Therapeutics (ERNA) generated about n/a in revenue and -$14 million in net income over the trailing twelve months, growing at roughly -51.3% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Eterna Therapeutics profitable?+

Eterna Therapeutics reported about -$14 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Eterna Therapeutics growing?+

Eterna Therapeutics's revenue has compounded at roughly -51.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ERNA's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 6 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 9 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ERNA

CompareIntrinsic value
ELABPMGC Holdings Inc.
$1.14-10.24%20
VCNXVaccinex, Inc.
$0.80-11.11%10
SLNSilence Therapeutics plc
$19.81+0.00%10
QUCYQuantum Cyber N.V.
$0.56+1.45%10
ONCOOnconetix Inc.
$2.89-8.54%50
IMNNImunon, Inc.
$0.54-6.05%10
MREOMereo BioPharma Group plc
$0.26-5.45%10
UNCYUnicycive Therapeutics Inc.
$3.35-5.10%10

Spot a number that looks wrong? Check it in ERNA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ERNA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.